Kyver­na Ther­a­peu­tics adds $60M to the bank as it pre­pares to show­case ear­ly CAR-T da­ta in lu­pus nephri­tis

Kyver­na Ther­a­peu­tics’ an­ti-CD19 CAR-T is draw­ing new in­vestors to lead a $60 mil­lion in­fu­sion, re­load­ing as it steers through ear­ly clin­i­cal tri­als in au­toim­mune dis­eases.

Bain Cap­i­tal Life Sci­ences and Gor­don­MD Glob­al In­vest­ments led the Se­ries B ex­ten­sion, which brought the round to $145 mil­lion.

Emeryville, CA-based Kyver­na counts it­self among the first wave of drug de­vel­op­ers re­pur­pos­ing CAR-T ther­a­pies — which have made waves in can­cer — to treat au­toim­mune dis­eases, in hopes of tap­ping open a broad new field for cell ther­a­py. With tri­als open in both the US and Ger­many, Kyver­na said it cur­rent­ly has sev­en pa­tients in treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER